1/15
08:43 am
nbix
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR [Yahoo! Finance]
1/15
08:30 am
nbix
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Medium
Report
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
1/12
01:46 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.
1/8
12:49 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.
1/8
08:02 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $175.00 price target on the stock, up previously from $173.00.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $175.00 price target on the stock, up previously from $173.00.
1/5
05:02 pm
nbix
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
04:01 pm
nbix
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/31
06:48 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/30
07:07 pm
nbix
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab [Yahoo! Finance]
Low
Report
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab [Yahoo! Finance]
12/22
04:11 pm
nbix
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy [Yahoo! Finance]
12/22
04:05 pm
nbix
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Low
Report
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
12/17
08:05 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
12/16
07:13 pm
nbix
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript [Seeking Alpha]
Medium
Report
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript [Seeking Alpha]
12/16
04:38 pm
nbix
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology [Yahoo! Finance]
12/16
04:01 pm
nbix
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Medium
Report
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
12/12
09:48 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a "neutral" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a "neutral" rating on the stock.
12/11
08:44 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
12/9
04:25 pm
nbix
Neurocrine Biosciences to Host R&D Day on December 16 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Host R&D Day on December 16 [Yahoo! Finance]
12/9
04:01 pm
nbix
Neurocrine Biosciences to Host R&D Day on December 16
Low
Report
Neurocrine Biosciences to Host R&D Day on December 16
12/8
09:56 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.
12/5
12:19 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.
11/28
04:33 am
nbix
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
Low
Report
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
11/20
08:30 am
nbix
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
11/18
04:57 pm
nbix
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
Low
Report
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
11/12
07:10 pm
nbix
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
Low
Report
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]